Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring
BETHLEHEM, Pa., Nov. 21, 2014 /PRNewswire/ -- Particle Sciences, Inc (PSI), the leading CDMO for drug eluting devices, has developed and manufactured a new innovative vaginal ring for Ladee Pharma Research Institute (LPRI), the Research and Development arm of Exeltis Pharmaceuticals. According to Bruce Frank, Vice President of Project Management at Particle Sciences, "This vaginal ring was developed for LPRI at Particle Sciences utilizing our material sciences and modeling expertise. We are thrilled it is now going into the clinic. The current production is for a significant Phase I/II study requiring over 12,000 rings." Under the agreement, PSI has developed and will produce the drug product for LPRI with eventual technical transfer to Exeltis for commercialization. Frank added, "This is one of multiple drug eluting vaginal ring products that PSI has taken to the clinic this year and our device group is currently working on others, along with several implants."
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered inBethlehem, Pennsylvania. Visit www.particlesciences.com, email email@example.com, or contact us at (610) 861- 4701 for information.
SOURCE Particle Sciences, Inc.